Search

H Lundbeck A-S

Closed

33.78 -2.76

Overview

Share price change

24h

Current

Min

33.2

Max

36.28

Key metrics

By Trading Economics

Income

-221M

590M

Sales

-181M

5.5B

P/E

Sector Avg

12.492

73.239

EPS

1.36

Dividend yield

1.78

Profit margin

10.648

Employees

5,707

EBITDA

-193M

811M

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.78%

3.06%

Market Stats

By TradingEconomics

Market Cap

38B

Previous open

36.54

Previous close

33.78

H Lundbeck A-S Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 Mar 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31 Mar 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Mar 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 Mar 2025, 22:28 UTC

Earnings

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke Swings to Loss for 2024 >000002.SZ

31 Mar 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 Mar 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 Mar 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 Mar 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31 Mar 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 Mar 2025, 21:02 UTC

Earnings

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 Mar 2025, 21:01 UTC

Earnings

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Mar 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 Mar 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 Mar 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 Mar 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 Mar 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 Mar 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 Mar 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 Mar 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 Mar 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 Mar 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31 Mar 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.